## **Trustees’ Annual Report for the period** ||**Period start date**|**Period start date**|**Period start date**|||**Period end date**|**Period end date**| |---|---|---|---|---|---|---|---| ||**Day**|**Month**|**Year**||**Day**|**Month**|**Year**| |**From**|23|June|2024|**To**|22|June|2025| ||||||||| |**Charity name**||||Radiotherapy UK|||| |**Other names charity is known by**||||ACCORN|||| |||||Action Radiotherapy|||| |**Charity registration number**||||1135902|||| ## **Objectives and Activities** ||SORP reference|| |---|---|---| |**Summary of the purposes of the**
**charity as set out in its governing**
**document**|Para 1.17|**1.**
**To promote, support and encourage research into**
**radiotherapy, radiobiology and allied subjects, and the**
**dissemination of the useful results of such research by**
**such actions as:**
a.
Promoting and facilitating multidisciplinary
collaboration between researchers and practitioners
in radiotherapy and its allied subjects
b.
Informing patients and the public about practice and
research in radiotherapy and its allied subjects, and
engaging patients and the public in the development
of research projects
c.
Awarding grants as appropriate
**2.**
**To advance and benefit the practice of radiotherapy and**
**its allied subjects to relieve sickness and preserve good**
**health by such actions as:**
a.
Promoting and facilitating multidisciplinary
networking and sharing of expertise and best
practice
b.
Promoting and encouraging the study of the science
and practice of radiotherapy and its allied subjects
c.
Promoting and facilitating increased involvement of
allied professions
d.
Facilitating development and dissemination of best
practices in radiotherapy and its allied subjects
e.
Disseminating knowledge concerning all aspects of
the science and practice of radiotherapy and its
allied subjects
f.
Promoting and facilitating education and training in
the research and practice of radiotherapy and its
allied subjects| |**Summary of the main actvites in**
**relaton to those purposes for the**
**public beneft, in partcular, the**
**actvites, projects or services**
**identfed in the accounts.**|Para 1.17 and
1.19|_1._
_Patent informaton resources_
We work to support patents with cancer through the
provision of trusted, accessible and relevant informaton
resources before, during and following their radiotherapy
treatment. We develop Patent Informaton Forum (PIF)
accredited resources that means patents and families can
trust that what we produce is evidence-based,
understandable, jargon-free, up-to-date and produced to the
best possible standard.
_2._
_Advocacy and Campaigning_
We work in partnership with patents, academics, workforce,
industry and parliamentarians to campaign for equality of
access to world-class radiotherapy for all patents with cancer
in the UK. We raise awareness of how harnessing
technologically advanced, cost-efectve radiotherapy could
treat more patents, quicker.
We are proud to be the charity partner of the
Radiotherapy4Life
campaign and
co-founder of the
#CatchUpWithCancer
campaign. As Secretariat for the APPG-
Radiotherapy we work with the Chair and Ofcers in
organising events, meetngs and ensuring all APPG regulatons
and requirements are met.
Our work also has global reach through our partnership with
the Global Coaliton for Radiotherapy as we support other
countries advocatng for increased access to radiotherapy
services.
_3._
_Workforce engagement and support_
Our work amplifes the voice of the frontline radiotherapy
workforce to raise awareness of the issues faced in the
delivery of services. We provide opportunites for the
workforce to learn and engage with ideas, innovatons and
technologies that can support them in developing patent-
centred care and practce. We ofer an actve network of
radiotherapy professionals who ofer peer support, educaton
and insight. We also promote careers in radiotherapy through
job listngs shared daily through our platorms and website.
_4.General fundraising/events_
The charity raises funds from a variety of sources including
online giving, community events, corporate partnerships,
legacies, individual donatons and grants. The charity was very
grateful to receive support in this fnancial year from B-Clear,
Ergea, Brainlab, Elekta, Varian-Siemens-Healthineers,
FlenHealth, Amethyst, AstraZeneca, Price-Jones, Accuray and
the Openworks Foundaton.
_5. Research and Data_
The charity delivers analysis on publicly available data such as
waitng-tmes for cancer treatment and produces evidence-
based reports and research to beter understand how
radiotherapy services are currently being delivered and what
needs to change to improvepatent outcomes and| |---|---|---| |||experience.
We collaborate and support research partners to co-design
and deliver patent-focused research projects.| |---|---|---| |**4**|Para 1.18|Radiotherapy UK has had regard to the guidance issued by the
Charity Commission on public beneft.
Radiotherapy UK is commited to making available to the
public, informaton regarding radiotherapy treatment and its
benefts, providing opportunites for radiotherapy
professionals to share informaton as well as campaign for
beter fundingfor radiotherapytreatment in the UK.| ## **Additional information (optional)** You may choose to include further statements where relevant about: |Contributon made by volunteers|Para 1.38|Volunteers are essental to our charity's success in delivering
services. We depend on them to lead our organizaton
through the Board, and to guide our eforts via the
Ambassadors network, as well as patent and clinical
engagementgroups.| |---|---|---| ## **Achievements and Performance** |**Achievements and Performance**|||| |---|---|---|---| ||SORP reference||| |Summary of the main
achievements of the charity,
identfying the diference the
charity’s work has made to the
circumstances of its benefciaries
and any wider benefts to society
as a whole.|Para 1.20||In additon to the actvites noted above
,the charity has
achieved the following this year for the beneft of patents,
professionals, and the wider community:
**Advocacy and Policy**

We co-ordinated three high-profle events at
Westminster, engaging over 75 MPs through our
#_CatchUpWithCancer_and_Radiotherapy4Life_
campaigns.

A major milestone was our_#CatchUpWithCancer_
Day
in Parliament
on World Cancer Day 2025, bringing
together over 20 cancer charites and earning
natonal media coverage for our analysis revealing
that more than 500,000 people have faced excessive
delays in cancer treatment over the past decade.

In Autumn 2025, thegovernment announced £70
million
for replacing radiotherapy machines,
refectng with one of our campaign’s key calls to
acton.

We amplifed our advocacy work at four major
conferences, presentng natonally and
internatonally—including UKIO, the SCOR Annual
Conference, and an Internatonal Cancer Expert
Corps event at CERN, Switzerland.

The charity supported the development of the
world’s frstWorld Radiotherapy Awareness Day| ||(WRAD). Developed in partnership with founding| |---|---| ||organisaton Global Coaliton for Radiotherapy, the| ||day highlighted the need for natonal and| ||internatonal advocacy to improve access to| ||radiotherapy for all patents globally.| ||Parliamentary engagement included 130 Writen| ||Questons and one dedicated debate on Accessibility| ||to Radiotherapy on World Cancer Day 2025.| ||Our_CatchUpWithCancer_petton surpassed 624,919| ||signatures onchange.org petton
.| ||We launched our landmark report,Unlocking| ||Modern Radiotherapy
,providing critcal analysis and| ||recommendatons to transform patent access.| ||Radiotherapy UK contnued as secretariat for theAll-| ||Party Parliamentary Group for Radiotherapy
(APPG-| ||RT). Following the electon of a new government, the| ||APPG was successfully reconsttuted, ending the| ||period with 41 MP members.| |**Patent**|**Informaton**| ||Launched ourPatents and Families Online Hub
– a| ||major milestone packed with resources to support| ||patents and their loved ones throughout the| ||radiotherapy pathway.| ||Successfully renewed our PIF TICK accreditaton| ||following rigorous independent assessment –| ||maintaining our status as a_trusted informaton_| ||_creator_and holding the UK’s only assessed quality| ||mark for health and care informaton.| ||Created over 45 new patent informaton resources,| ||ensuring clarity and accessibility for those navigatng| ||treatment.| ||Hosted 8 meetngs of our Patent Engagement| ||Group, strengthening patent voice in our work.| ||Engaged 10 patent reviewers and 20 clinical| ||reviewers to support the development of high-| ||quality patent informaton resources.| ||Our new Patents and Families Online Hub have| ||driven signifcant increase in visits to our website| ||with 56,000 new users over this period, representng| ||a 40% increase in new users from previous period_._| ||We are project partners of the GRACE project,| ||(Gynae Radiotherapy Consent Enhancement),| ||research led by Lancaster and Bangor universites| ||and funded by NIHR. GRACE aims to improve how| ||patents make informed decisions about| ||radiotherapy for gynaecological cancer, with input| ||from clinical experts, researchers, those with lived| ||experience and thepublic.| ## **Workforce Engagement** ||Delivered four RTUK Talks webinars, atractng 1,221| |---|---| ||registratons and generatng 479 YouTube views,| ||providing valuable learning and networking| ||opportunites for the radiotherapy workforce.| ||Expanded our Workforce Ambassadors programme,| ||now engaging 50 ambassadors who champion best| ||practce and workforce development across the UK.| ||Launched the 2024 Flash Workforce Survey, with| ||responses from just under 10% of the workforce,| ||helping to inform and strengthen our advocacy work| ||by amplifying the voice of frontline professionals.| |**Communicatons and Awareness**|| ||Maintained a strong media presence, with regular| |---|---| ||coverage in natonal news and major print| ||publicatons._(All coverage is availablehere_
_.)_| ||Signifcant growth across key digital channels, in line| ||with our communicatons strategy:| ||`o`
Daily News: 1,964 subscribers| ||`o`
Instagram: 22% increase in followers (from| ||2,538 to 3,100)| ||`o`
LinkedIn: 24.3% growth (from 6,554 to| ||8,153 followers)| ||`o`
Facebook: 6.5% growth (from 2,538 to| ||3,100 followers)| ||Website trafc surged, with a 40% increase in new| ||users, reaching 56,000.| ||YouTube engagement grew, with 9,406 views and| ||485.9 watch hours, expanding our reach through| ||video content.| |**ern**|**ance**| ||Recruited six new Board members, bringing fresh| ||expertse and perspectves to strengthen leadership| ||and oversight.| ||Developed the 2025–2028 Strategic Plan, setng a| ||clear roadmap for growth, impact, and sustainability.| ## **Governance** |Additional information (optional)
You may choose to include further statements where relevant about:|Additional information (optional)
You may choose to include further statements where relevant about:|Additional information (optional)
You may choose to include further statements where relevant about:| |---|---|---| |Achievements against objectves
set|Para 1.41|N/A| |Performance of fundraising
actvites against objectves set|Para 1.41|N/A| |Other||Corporate Partnerships
The charity benefts from several corporate partnerships for
example Varian (Siemens Healthineers) and Ergea co-sponsor
the charity’s Daily News bulletn. All these partnerships are
agreed on a vendor neutral basis.| |**Financial Review**||| |Review of the charity’s fnancial
positon at the end of the period|Para 1.21|The Charity’s total income for this fnancial year was
£214,611. Total expenditure for this year was £201,658
leaving the charity with a year-end net proft of £12,953
During 2024/2025 The Charity has managed to contnue its
work within budget by using its contacts and generous
donatons in kind (resources) from Price Jones Ltd.
With the current economic constraints and cost of living crisis
this is a challenging tme for charity income generaton.
However, the charity is confdent that there are untapped
avenues of funding available to the organisaton. In this year
the charity hired a part-tme fundraiser to support with
accessing this funding.| |Statement explaining the policy for
holding reserves statng why they
are held|Para 1.22|Radiotherapy UK’s policy is to provide the charity with
adequate fnancial stability and the means for it to meet its
charitable objectves. Except for such funds as the Trustees
consider prudent to maintain for the purposes of
management and administraton of the charity for the
foreseeable future, all unrestricted funds are used to the
purpose of general objects of the charity. The adequacy of the
reserves is reviewed annually.| |Amount of reserves held|Para 1.22|£163,577 (excluding the related party loan mentoned below)| |Details of fund materially in defcit|Para 1.24|The Charity has a long-term interest-free loan from related
party Price Jones Ltd which is repayable at £2,500pa. The
balance at June 2025 is £12,672.| |Explanaton of any uncertaintes
about the charity contnuing as a
goingconcern|Para 1.23|There are no current uncertaintes regarding the charity
contnuing as a going concern.| |**Additional information (optional)**
You may choose to include further statements where relevant about:||| |The charity’s principal sources of
funds(includinganyfundraising)|Para 1.47|The Charity’s main source of funds for this reportng period
were:| |||1.
Public Donatons via online giving and community events.
2.
Corporate donatons
3.
Legacies| |---|---|---| |Investment policy and objectves
including any social investment
policyadopted|Para 1.46|We do not currently hold enough reserves to warrant an
investment policy.| |||| |A descripton of the principal risks
facing the charity|Para 1.46|**Current Challenges**
1.
**Balancing growth with fnancial constraints**– expanding
services while managing limited resources.
2.
**Strained fundraising environment**– cost-of-living crisis
and economic uncertainty making donor engagement
and income generaton more difcult.
3.
**Maintaining benefciary engagement**– ensuring patents
and service users remain actvely involved in services and
organisatonal development.
4.
**Strengthening governance structures**– adaptng policies
and oversight to match organisatonal growth and
complexity.
5.
**Navigatng a shifing politcal and health landscape**–
responding to policy changes and advocacy needs in an
unpredictable environment both natonally and
geopolitcally.
6.
**Healthcare system pressures**– ongoing crisis in cancer
service delivery, compounded by workforce strikes,
excessive bureaucracy, leadership gaps, and minimal
investment.
7.
**Keeping pace with technology and AI**– leveraging digital
tools and artfcial intelligence for service delivery,
fundraising, and communicatons while managing costs,
skills gaps, and ethical consideratons.| 1. ||Other||**Future initatves**
1.
**Implement Year One of the 2025–2028 Strategic**
**Plan**, setng the foundaton for long-term impact.
2.
**Develop new income generaton streams**to
strengthen fnancial sustainability and support
service growth.
3.
**Engage with the new Cancer Control Plan**, ensuring
our approach is evidence-based and data-driven.
4.
**Deliver new patent informaton resources**,
including comprehensive skin-care guidelines and a
major project on internal radiotherapy.
5.
**Expand collaboraton with like-minded**
**organisatons**, natonally and internatonally, to
amplify reach and infuence.
6.
**Contnue campaigning and advocacy eforts**to
secure improved access to high-quality radiotherapy
services across the UK.
7.
**Strengthen workforce engagement**through the
contnued growth of our Workforce Ambassadors
Programme, supportng professional development
and advocacy.
8.
**Advance the APPG-RT programme of work**, with a
focus on tackling inequalites in access to
radiotherapy services.
9.
**Collaborate with research partners across all areas**,
including projects aimed at improving patent
experience and supportng the adopton of new
radiotherapy techniques.|| |---|---|---|---|---| |||||| ## **Structure, Governance and Management** |**Descripton of charity’s trusts:**||| |---|---|---| |**Type of governing document**
**(trust deed, royal charter)**|Para 1.25|Consttuton| |**How is the charity consttuted?**
**(e.g. unincorporated associaton,**
**CIO)**|Para 1.25|Associaton| |**Trustee selecton methods**
**including details of any**
**consttutonal provisions e.g.**
**electon to post or name of any**
**person or body enttled to**
**appoint one or more trustees**|Para 1.25|Original Trustees were nominated and elected by the
ACORRN Scientfc Steering Commitee. New Trustees are
nominated by the same process and are elected by
consensus of the Board of Trustees of Radiotherapy UK.| ## **Reference and Administrative details** |Charityname|RadiotherapyUK(previouslyActon Radiotherapy)| |---|---| |Other name the charityuses|ACORRN| |Registered charitynumber|1135902| |Charity’s principal address|4 Abbotsbury House
139 Abbotsbury Road
London W14 8EN| ## **Names of the charity trustees who manage the charity** |1
2
3
4
5
6
7
8
9
10
11|**Trustee name**|**Ofce (if any)**|**Dates acted if not for**
**whole year**|**Name of person (or body)**
**enttled to appoint trustee (if**
**any)**| |---|---|---|---|---| ||Professor Patricia Price|Chair||Board of Trustees| ||Dr Christy Goldsmith|Secretary||Board of Trustees| ||Ms Tanya Levine|Treasurer||Board of Trustees| ||Dr Clive Harmer||Resigned 1.2.25|Board of Trustees| ||Professor Philip Mayles|||Board of Trustees| ||Victoria Chapman||Appointed 12.9.24|Board of Trustees| ||Samina Hussain||Appointed 12.9.24|Board of Trustees| ||Professor Andrew Beavis||Appointed 12.9.24|Board of Trustees| ||Adele Lyons||Appointed 12.9.24|Board of Trustees| ||Andy Tudor||Appointed 12.9.24|Board of Trustees| ||Dr Clare Louise Hague||Appointed 12.9.24|Board of Trustees| ## **Funds held as custodian trustees on behalf of others** |Descripton of the assets held in
this capacity|None| |---|---| |Name and objects of the charity on
whose behalf the assets are held
and how this falls within the
custodian charity’s objects|None| |Details of arrangements for safe
custody and segregaton of such
assets from the charity’s own
assets|None| ## **Additional information (optional)** **Names and addresses of advisers (Optional information)** **----- Start of picture text -----**
Type of adviser Name Address
**----- End of picture text -----**
**Name of chief executive or names of senior staff members (Optional information)** Sarah Quinlan – Charity Director ## **Exemptions from disclosure** Reason for non-disclosure of key personnel details **Other optional information** **Declarations** |**The trustees declare that they have approved the trustees’ report above.**
**Signed** **on behalf of the charity’s trustees**
~~oo~~|**The trustees declare that they have approved the trustees’ report above.**
**Signed** **on behalf of the charity’s trustees**
~~oo~~|**The trustees declare that they have approved the trustees’ report above.**
**Signed** **on behalf of the charity’s trustees**
~~oo~~| |---|---|---| |**Signature(s)**||| |**Full name(s)**|Professor Pat Price|| |**Position (e.g. Secretary, Chair, etc**|Chair|| |**Date**|16 December 2025|| **Radiotherapy UK** **Receipts and pay** 23.06.2024 **For the period from** ~~ee~~ ## ~~a~~ **Section A Receipts and payments Unrestricted Restricted funds funds** **to the nearest £** ## **to the nearest £** ## **A1 Receipts** |**A1 Receiptsptsts**|||| |---|---|---|---| |Corporate donations|**156,167**||**-**| |Community|**22,814**||**-**| |Trusts & Foundations|**5,599**||**-**| |Legacies|**30,000**||**-**| |Interest Income|**31**||**-**| ||**-**||**-**| ||**-**||**-**| **214,611 -** _**Sub total** (Gross income for AR)_ |**214,611**
**-**
**_Sub total_**_(Gross income for AR)_|**214,611**
**-**
**_Sub total_**_(Gross income for AR)_|**214,611**
**-**
**_Sub total_**_(Gross income for AR)_|**214,611**
**-**
**_Sub total_**_(Gross income for AR)_|**214,611**
**-**
**_Sub total_**_(Gross income for AR)_|**214,611**
**-**
**_Sub total_**_(Gross income for AR)_|**214,611**
**-**
**_Sub total_**_(Gross income for AR)_|**214,611**
**-**
**_Sub total_**_(Gross income for AR)_|**214,611**
**-**
**_Sub total_**_(Gross income for AR)_| |---|---|---|---|---|---|---|---|---| |**-**
**-**
**-**
**-**
**_Sub total_ -**
**-**
**A2 Asset and investment sales, (see**
**table).**
~~————~~||||||||| ||**_Total receipts_ 214**
**A3 Payments**||**214,611**
~~ee ~~||||||**-**| ||Advocacy& campaigning|||**22,018**||||**-**| ||Charityrunningcosts|||**4,690**||||**-**| ||Communications|||**5,550**||||**-**| ||Contractors|||**76,071**||||**-**| ||Incomegeneration|||**89**||||**-**| ||IT & development|||**2,250**||||**-**| ||Patient services|||**920**||||**-**| ||Professional fees|||**5,105**||||**-**| ||Promotional materials|||**2,979**||||**-**| ||Research & Data analytics|||**-**||||**-**| ||Salaries|||**73,431**||||**-**| ||Workforce services|||**2,248**||||**-**| ||Training& development|||**3,807**||||**-**| ||Loan repayment|||**2,500**||||**-**| > _**Sub total**_ ~~ee~~ **201,658** ~~|~~ **-** **A4 Asset and investment purchases, (see table)** Computer equipment **-** ~~—————~~ |**_Sub total_ -**
**_Total payments_ 201,658**
**_Net of receipts/(payments)_ 12,953**
**A5 Transfers between funds**
**-**
**A6 Cash funds last year end**
**150,624**
**_Cash funds this year end_ 163,577**|**-**| |---|---| ||| ||**-**| ||| ||**-**| ||**-**| ||**-**| ||**-**| ## **Section B Statement of assets and liabilities at the end** ## **Categories** ## **Details** **B1 Cash funds** Bank ## _**Total cash funds**_ (agree balances with receipts and payments account(s)) ## **Details** **B2 Other monetary assets** ## **Details** ## **B3 Investment assets** ## **Details** **B4 Assets retained for the charity’s own use** ## **Details** ## **B5 Liabilities** Signed by one or two trustees on behalf of all the trustees Loan due to Professor Pat Price Limited Signature **1135902 ments accounts** 22.06.2025 **To** **CC16a** ## **Endowment funds Total funds** ## **Last year** **to the nearest £ to the nearest £ to the nearest £** |**-**||**156,167**||**91,431**| |---|---|---|---|---| |**-**||**22,814**||**23,208**| |**-**||**5,599**||**2,470**| |**-**||**30,000**||| |**-**||**31**||**-**| |**-**||**-**||**-**| |**-**||**-**||**-**| |**-**||**214,611**||**117,110**| ||**-**||||**-**|||||| |---|---|---|---|---|---|---|---|---|---|---| ||**-**||||**-**||||**-**|| ||**-**||||**-**||||**-**|| |||||||||||| ||**-**||||**214,611**||||**117,110**|| ||**-**||||**22,018**||||**11,537**|| |---|---|---|---|---|---|---|---|---|---|---| ||**-**||||**4,690**||||**5,626**|| ||**-**||||**5,550**||||**8,318**|| ||**-**||||**76,071**||||**60,127**|| ||**-**||||**89**||||**1,409**|| ||**-**||||**2,250**||||**5,734**|| ||**-**||||**920**||||**629**|| ||**-**||||**5,105**||||**3,708**|| ||**-**||||**2,979**||||**823**|| ||**-**||||**-**||||**7,200**|| ||**-**||||**73,431**||||**53,617**|| ||**-**||||**2,248**||||**255**|| ||**-**||||**3,807**||||**30**|| ||**-**||||**2,500**||||**2,500**|| |||||||||||| ||**-**||||**201,658**||||**161,511**|| |||||||||||| |**-**||**-**||**1,247**| |---|---|---|---|---| |**-**||**-**||| |||**1,247**| |---|---|---| |||| |||**162,758**| |||| |**12,953**||**- 45,650**| |**-**||**-**| |**150,624**||**196,275**| |**163,577**||**150,625**| |**of the period**||| |---|---|---| |**to nearest £**
**-**
**-**
**163,577**
OK
**to nearest £**
**-**
**-**
**-**
**-**
**-**
**-**
**Unrestricted**
**funds**
**Unrestricted**
**funds**|**Restricted funds**
**to nearest £**
**-**
**-**
**-**
**-**
OK
**Restricted funds**
**to nearest £**
**-**
**-**
**-**
**-**
**-**
**-**|**to nearest £**
**Endowment**
**funds**| |||**-**| |||**-**| |||**-**| |||**-**| |||OK| |||**to nearest £**
**Endowment**
**funds**| |**-**|**-**|**-**| |**-**|**-**|**-**| |**-**|**-**|**-**| |**-**|**-**|**-**| |**-**|**-**|**-**| |**-**|**-**|**-**| |**Fund to which asset**
**belongs**
**Fund to which asset**
**belongs**|**Cost (optional)**
**-**
**-**
**-**
**-**
**-**
**Cost (optional)**
**-**
**-**
**-**|**Current value**
**(optional)**| |---|---|---| |||**-**| |||**-**| |||**-**| |||**-**| |||**-**| |||**Current value**
**(optional)**| ||**-**|**-**| ||**-**|**-**| ||**-**|**-**| |**-**||**-**| |---|---|---| |**-**||**-**| |**-**||**-**| |**-**||**-**| |**-**||**-**| |**-**||**-**| |**Fund to which liability**
**relates**|**12,672**
**-**
**-**
**-**
**-**
**Amount due**
**(optional)**|**When due (optional)**| |---|---|---| ||**12,672**|| ||**-**|| ||**-**|| ||**-**|| ||**-**|| Print Name Date of approval ## **Independent Examiner's Report to the Trustees of Radiotherapy UK** I report to the trustees on my examination of the accounts of Radiotherapy UK for the year ended 22 June 2025. ## **Responsibilities and basis of report** As the charity trustees you are responsible for the preparation of the accounts in accordance with the requirements of the Charities Act 2011. (‘the Act’). I report in respect of my examination of the Trust’s accounts carried out under section 145 of the 2011 Act and in carrying out my examination I have followed all the applicable Directions given by the Charity Commission under section 145(5)(b) of the Act. ## **Independent examiner’s statement** I have completed my examination. I confirm that no material matters have come to my attention in connection with the examination giving me cause to believe that in any material respect: 1. Accounting records were not kept in respect of the Trust as required by section 130 of the Act; or 2. The accounts do not accord with those records. I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report to enable a proper understanding of the accounts to be reached. Susan Redmond FCA DJH Manchester Limited St George's House 56 Peter Street Manchester M2 3NQ 9[th ] January 2026 ## **RADIOTHERAPY UK YEAR ENDED 22 JUNE 2025 NOTES TO ACCOUNTS** ## **Interest-free loan** The charity received an interest-free loan from Price Jones Limited, a company in which one of the trustees Professor Patricia Price is a director and shareholder. The loan currently stands at £12,672 and is repayable at £2,500 per annum beginning 1 July 2017. ## **Related party transactions** During the year there was a further £2,374 (2024: £4,676) paid to Professor Pat Price Limited. These were for general administrative costs. All transactions were considered to be at arm’s length. During the year donations of £38,017 (2024:£40,000) were received from Radiotherapy4Life Limited, a company in which one of the trustees Patricia Price is a director and shareholder. Donations of £5,000 were received from Professor Pat Price Limited, a company in which Patricia Price is also a director.